Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

Nature Medicine

Volumn 20, Issue 6, 2014, Pages 607-615

  Motz, Gregory T ^a   Santoro, Stephen P ^a   Wang, Li Ping ^b   Garrabrant, Tom ^a   Lastra, Ricardo R ^b   Hagemann, Ian S ^b   Lal, Priti ^b   Feldman, Michael D ^b   Benencia, Fabian ^a   Coukos, George ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; INTERLEUKIN 10; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

MUS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES; APOPTOSIS; BLOTTING, WESTERN; ENDOTHELIUM, VASCULAR; FAS LIGAND PROTEIN; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; JURKAT CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROARRAY ANALYSIS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902124970     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3541     Document Type: Article

References (49)

1. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
2. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003). (Pubitemid 36077915)
3. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102, 18538-18543 (2005). (Pubitemid 43011261)
4. Hwang, W.T., Adams, S.F., Tahirovic, E., Hagemann, I.S. & Coukos, G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 124, 192-198 (2012).
5. Cipponi, A., Wieers, G., van Baren, N. & Coulie, P.G. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol. Immunother. 60, 1153-1160 (2011).
6. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006). (Pubitemid 44498003)
7. Boissonnas, A., Fetler, L., Zeelenberg, I.S., Hugues, S. & Amigorena, S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J. Exp. Med. 204, 345-356 (2007). (Pubitemid 46294550)
8. Shrimali, R.K. et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171-6180 (2010).
9. Molon, B. et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208, 1949-1962 (2011).
10. Motz, G.T. & Coukos, G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11, 702-711 (2011).
11. Facciabene, A. et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 475, 226-230 (2011).
12. Bouma-ter Steege, J.C. et al. Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin. Cancer Res. 10, 7171-7178 (2004).
13. Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410-414 (2008). (Pubitemid 351693122)
14. Buckanovich, R.J. et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14, 28-36 (2008).
15. Quezada, S.A. et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205, 2125-2138 (2008).
16. Bouzin, C., Brouet, A., De Vriese, J., Dewever, J. & Feron, O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J. Immunol. 178, 1505-1511 (2007). (Pubitemid 46154621)
17. Griffioen, A.W., Damen, C.A., Martinotti, S., Blijham, G.H. & Groenewegen, G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 56, 1111-1117 (1996). (Pubitemid 26065408)
18. Shetty, S. et al. Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J. Immunol. 186, 4147-4155 (2011).
19. Strasser, A., Jost, P.J. & Nagata, S. The many roles of FAS receptor signaling in the immune system. Immunity 30, 180-192 (2009).
20. Yu, J.S. et al. Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium. J. Neurooncol. 64, 55-61 (2003). (Pubitemid 36992460)
21. Bajou, K. et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 14, 324-334 (2008).
22. Sata, M., Luo, Z. & Walsh, K. Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J. Immunol. 166, 6964-6971 (2001). (Pubitemid 32467244)
23. Yang, J. et al. Endothelial cell overexpression of fas ligand attenuates ischemia-reperfusion injury in the heart. J. Biol. Chem. 278, 15185-15191 (2003). (Pubitemid 36799853)
24. Abrahams, V.M. et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res. 63, 5573-5581 (2003). (Pubitemid 37139880)
25. Gupta, R.A. et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 63, 906-911 (2003). (Pubitemid 36278417)
26. Zhang, L. et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am. J. Pathol. 161, 2295-2309 (2002). (Pubitemid 35434873)
27. Lam, C.T. et al. Brain-derived neurotrophic factor promotes tumorigenesis via induction of neovascularization: implication in hepatocellular carcinoma. Clin. Cancer Res. 17, 3123-3133 (2011).
28. Tei, K. et al. Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats. Cancer Res. 62, 6289-6296 (2002). (Pubitemid 35244483)
29. Turk, M.J. et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200, 771-782 (2004). (Pubitemid 39299463)
30. Gaugler, M.H. A unifying system: does the vascular endothelium have a role to play in multi-organ failure following radiation exposure? BJR Suppl. 27, 100-105 (2005).
31. Huang, X. et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J. Exp. Med. 207, 505-520 (2010).
32. Restifo, N.P. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. 6, 493-495 (2000). (Pubitemid 30305889)
33. Herrero, R. et al. The biological activity of FasL in human and mouse lungs is determined by the structure of its stalk region. J. Clin. Invest. 121, 1174-1190 (2011).
34. Suda, T., Hashimoto, H., Tanaka, M., Ochi, T. & Nagata, S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186, 2045-2050 (1997). (Pubitemid 28013689)
35. Chappell, D.B., Zaks, T.Z., Rosenberg, S.A. & Restifo, N.P. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 59, 59-62 (1999). (Pubitemid 29062956)
36. Andreola, G. et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195, 1303-1316 (2002). (Pubitemid 34564332)
37. Favre-Felix, N. et al. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J. Immunol. 164, 5023-5027 (2000). (Pubitemid 30305173)
38. Donskov, F. et al. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack. Clin. Cancer Res. 10, 7911-7916 (2004). (Pubitemid 39587530)
39. Lurquin, C. et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201, 249-257 (2005). (Pubitemid 40189434)
40. Boon, T., Coulie, P.G., Van den Eynde, B.J. & van der Bruggen, P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175-208 (2006).
41. Dudley, M.E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002). (Pubitemid 35231542)
42. Manning, E.A. et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 13, 3951-3959 (2007). (Pubitemid 47037603)
43. Griffioen, A.W., Damen, C.A., Blijham, G.H. & Groenewegen, G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88, 667-673 (1996). (Pubitemid 26240398)
44. Basu, G.D. et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 177, 2391-2402 (2006). (Pubitemid 44201000)
45. Rini, B.I. et al. Phase III trial of bevacizumab plus interferon-α versus interferon-α monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28, 2137-2143 (2010).
46. Ades, E.W. et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 99, 683-690 (1992). (Pubitemid 23002027)
47. Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471 (1998). (Pubitemid 28471781)
48. + responder cells by Fas-mediated apoptosis. J. Immunol. 182, 1469-1480 (2009).
49. Motz, G.T. et al. Persistence of lung CD8 T cell oligoclonal expansions upon smoking cessation in a mouse model of cigarette smoke-induced emphysema. J. Immunol. 181, 8036-8043 (2008).